-

Gold Standard Diagnostics Receives FDA 510K for Lyme IgG and IgM EIA Kits

DAVIS, Calif.--(BUSINESS WIRE)--The Gold Standard Diagnostics Group (GSD) today announced the immediate availability of their two new Lyme IgG and Lyme IgM EIA kits for detection of antibodies against Lyme disease causing bacteria. The two assays give laboratories a more diverse arsenal of testing methodologies that allows them to achieve more reliable results. The assays are available immediately in the US.

The separate IgG and IgM assays provide laboratories the ability to offer more specificity in their Lyme screen algorithm. They are designed for optimal functionality in diagnostic laboratories with a total incubation time of 45 minutes at room temperature with ready-to-use controls. The kits can be run manually or on any open automated EIA platform.

While the world still grapples with COVID-19, many other medical conditions, including Lyme disease, are on the rise and are often undiagnosed. Experts have recently found, Americans infected with Lyme disease is ten times higher than what is reported by the CDC. What is more, symptoms of Lyme disease are so varied that it is often quite challenging to diagnose and can range from fever and headaches to irregular heartbeats, dizziness, and nerve pain. The GSD Lyme IgG and Lyme IgM EIA assays were made to provide antibody specific reliable information to the clinicians diagnosing this disease.

“We are witness to major changes in Lyme diagnostics. Our team of professionals are adapting and responding to these changes. New products are being produced to meet these new demands. GSD has an ever-expanding Lyme product menu to address and exceed laboratory expectations for Lyme and other tick-borne disease testing,” states Dr. Barry Menefee, Infectious Disease Specialist at GSD.

Traditional Lyme testing is our core. New and innovative Lyme testing will soon be available from GSD. For more information on these kits and GSD’s other Lyme products local GSD representative, email USSales@gsdx.us, or www.gsdx.us.

Contacts

Thomas Crowley
530-759-8000
USSales@gsdx.us

Gold Standard Diagnostics Group


Release Versions

Contacts

Thomas Crowley
530-759-8000
USSales@gsdx.us

More News From Gold Standard Diagnostics Group

Improved Lyme Screening Assay Now FDA Cleared for Laboratory Use

DAVIS, Calif.--(BUSINESS WIRE)--Gold Standard Diagnostics (GSD) today announced it offers a new B. burgdorferi VlsE-OspC IgG/IgM recombinant ELISA Screen that can be used to improve workflow and conserve testing resources. This assay has demonstrated increased sensitivity for early Lyme Disease detection - up to 20% over existing available Lyme screening assays - while maintaining 98% specificity. True Lyme negative samples are eliminated prior to second-tier testing. The OspC antigen used in t...

Gold Standard Diagnostics Announces FDA Clearance of the B. burgdorferi IgG/IgM VlsE-OspC EIA Test

DAVIS, Calif.--(BUSINESS WIRE)--Gold Standard Diagnostics (GSD), a Eurofins Technologies company, today announced FDA clearance of a new B. burgdorferi IgG/IgM VlsE-OspC EIA test. This test, when used in conjunction with the other FDA cleared GSD Lyme EIA tests can be used in the CDC recommended modified two-tiered testing (MTTT) algorithm. In 2014, the CDC issued an updated recommendation for the serologic diagnosis of Lyme disease, endorsing the use of a two-tier testing algorithm that uses a...

Gold Standard Diagnostics Multiplex Real-Time PCR Assay for SARS-CoV-2 Pathogen Detection Now Available in the US

DAVIS, Calif.--(BUSINESS WIRE)--Gold Standard Diagnostics Inc. today announced the EUA submission of a Multiplex Real-Time, reverse-transcriptase polymerase chain reaction (RT-PCR) assay for the direct qualitative pathogen detection of the novel coronavirus (SARS-CoV-2). The assay is available now for purchase in the U.S. Particularly in the early phase of COVID-19 infection, the direct and precise diagnostic of the pathogen is critical. PCR is the method of choice to detect acute coronavirus i...
Back to Newsroom